Organic field-effect transistor (OFET) biosensors have emerged as a transformative technology for clinical biomarker detection, offering unprecedented sensitivity, selectivity, and versatility in point-of-care (POC) diagnostics. This review examines the fundamental principles, materials innovations, device architectures, and clinical applications of OFET-based biosensing platforms. The unique properties of organic semiconductors, combined with advanced biorecognition strategies, enable the detection of clinically relevant biomarkers at low concentrations. Recent developments in organic semiconductor materials have significantly enhanced device performance and stability. The integration of novel device architectures such as electrolyte-gated OFETs (EGOFETs) and extended-gate configurations has expanded the operational capabilities of these sensors in aqueous environments. Clinical applications span a broad spectrum of biomarkers, demonstrating the versatility of OFET biosensors in disease diagnosis and monitoring. Despite remarkable progress, challenges remain in terms of long-term stability, standardization, and translation to clinical practice. The convergence of organic electronics, biotechnology, and clinical medicine positions OFET biosensors as a promising platform for next-generation personalized healthcare and precision medicine applications.
Sengupta et al. (2025) studied this question.